Advertisement

Index by author

October 01, 2024; Volume 391,Issue 1

  1. Gannon, Brenda M.

    1. A “Furious” Effort to Develop Novel 3,4-Methylenedioxymethamphetamine-Like Therapeutics
      William E. Fantegrossi and Brenda M. Gannon
      Journal of Pharmacology and Experimental Therapeutics October 2024, 391 (1) 18-21; DOI: https://doi.org/10.1124/jpet.124.002183

  2. Giembycz, Mark A.

    1. Comparison of the Genomic Activity of an EP4-Receptor and β2-Adrenoceptor Agonist in BEAS-2B Human Bronchial Epithelial Cells: In Search of Compartmentalized, cAMP-Dependent Gene Expression
      Radhika Joshi, Tamkeen U. Paracha, Mahmoud M. Mostafa, Andrew J. Thorne, Varuna Jayasinghe, Dong Yan, Omar Hamed, Robert Newton and Mark A. Giembycz
      Journal of Pharmacology and Experimental Therapeutics October 2024, 391 (1) 64-81; DOI: https://doi.org/10.1124/jpet.124.002226

  3. Gohdes, Mark A.

    1. Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway
      Open Access
      Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway
      Jim Zheng, Bing Lu, Gavin Carr, Judy Mwangi, Kelly Wang, Jia Hao, Kelly McLennan Staiger, Nathan Kozon, Bernard P. Murray, Mohammad Bashir, Mark A. Gohdes, Winston C. Tse, Scott Schroeder, Michael Graupe, John O. Link, Jungjoo Yoon, Anna Chiu, William Rowe, Bill J. Smith and Raju Subramanian
      Journal of Pharmacology and Experimental Therapeutics October 2024, 391 (1) 91-103; DOI: https://doi.org/10.1124/jpet.124.002302

  4. Graupe, Michael

    1. Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway
      Open Access
      Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway
      Jim Zheng, Bing Lu, Gavin Carr, Judy Mwangi, Kelly Wang, Jia Hao, Kelly McLennan Staiger, Nathan Kozon, Bernard P. Murray, Mohammad Bashir, Mark A. Gohdes, Winston C. Tse, Scott Schroeder, Michael Graupe, John O. Link, Jungjoo Yoon, Anna Chiu, William Rowe, Bill J. Smith and Raju Subramanian
      Journal of Pharmacology and Experimental Therapeutics October 2024, 391 (1) 91-103; DOI: https://doi.org/10.1124/jpet.124.002302

  5. Graves, Steven M.

    1. Levetiracetam Prevents Neurophysiological Changes and Preserves Cognitive Function in the Human Immunodeficiency Virus (HIV)-1 Transactivator of Transcription Transgenic Mouse Model of HIV-Associated Neurocognitive Disorder
      Levetiracetam Prevents Neurophysiological Changes and Preserves Cognitive Function in the Human Immunodeficiency Virus (HIV)-1 Transactivator of Transcription Transgenic Mouse Model of HIV-Associated Neurocognitive Disorder
      Ashley N. Ewens, Alexander Pilski, Shayne D. Hastings, Chris Krook-Magnuson, Steven M. Graves, Esther Krook-Magnuson and Stanley A. Thayer
      Journal of Pharmacology and Experimental Therapeutics October 2024, 391 (1) 104-118; DOI: https://doi.org/10.1124/jpet.124.002272
Back to top

In this issue

Advertisement